购物车
您的购物车当前为空
别名 埃克莱利尤单抗, NVP-CSJ117, CSJ-117
Ecleralimab 是一种针对胸腺基质淋巴细胞生成素 (TSLP) 的高效吸入型抗体片段 (scFv),通过阻断 TSLP 与其受体复合物结合发挥作用。该化合物是研究气道上皮源性细胞因子在哮喘发病机制中作用的重要工具,旨在通过抑制上游免疫级联反应来减轻 2 型炎症反应。
Ecleralimab 是一种针对胸腺基质淋巴细胞生成素 (TSLP) 的高效吸入型抗体片段 (scFv),通过阻断 TSLP 与其受体复合物结合发挥作用。该化合物是研究气道上皮源性细胞因子在哮喘发病机制中作用的重要工具,旨在通过抑制上游免疫级联反应来减轻 2 型炎症反应。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,900 | 2-4周 | |
| 5 mg | ¥ 7,630 | 2-4周 | |
| 10 mg | ¥ 12,300 | 2-4周 |
| 产品描述 | Ecleralimab is a potent inhaled antibody fragment (scFv) targeting TSLP, acting by blocking the binding of TSLP to its receptor complex. The compound is an essential tool for investigating the role of airway epithelial-derived cytokines in asthma pathogenesis, aiming to alleviate Type 2 inflammatory responses by inhibiting the upstream immune cascade. |
| 别名 | 埃克莱利尤单抗, NVP-CSJ117, CSJ-117 |
| 反应种属 | Human |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG1-KR-EPKSC |
| 偶联 | Unconjugated |
| Uniprot ID | |
| 靶点 | TSLP |
| CAS No. | 2415207-91-7 |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多